In this trial, Serp-1 was administered immediately after coronary stent implant in patients with unstable coronary syndromes, unstable angina, and non-ST elevation myocardial infarctions, where acute chronic plaque inflammation is seen [53]. This evidence concerns the gene SERP1 and ST Elevation Myocardial Infarction.